Jupiter Neurosciences secures exclusive U.S. rights to ALA-002

Jupiter Neurosciences said Tuesday it signed a definitive license agreement for perpetual exclusive U.S. rights to ALA-002 from PharmAla Biotech Holdings. The deal could be worth up to $100 million and gives Jupiter a second clinical-stage CNS asset alongside its Parkinson’s program.

Why it matters: - Jupiter Neurosciences is moving from a single-program clinical company to a dual clinical-stage CNS developer. - The deal adds a patented psychedelic asset with FDA Novel Chemical Entity designation, which can provide regulatory protection and potential commercial differentiation. - The agreement gives Jupiter perpetual exclusive U.S. rights, creating a potential long-term U.S. commercialization path. - The transaction comes as U.S. policy is becoming more supportive of investigational psychedelic therapies.

What happened: - Jupiter Neurosciences entered into a definitive license agreement with PharmAla Biotech Holdings for ALA-002. - The agreement covers perpetual exclusive rights in the United States. - Jupiter said the transaction could reach up to $100 million, including milestone payments and excluding ongoing royalties. - The company said the deal expands its portfolio alongside its natural resveratrol program and its Parkinson’s disease program.

The details: - Jupiter will make a $3.3 million upfront payment, including $1.5 million in cash and $1.8 million in JUNS common stock. - The stock portion carries a 120-day lock-up. - Jupiter will owe $3.3 million if ALA-002 reaches first patient in a Phase 3 study. - Jupiter will owe $20 million upon U.S. NDA approval. - Commercial milestones total $10 million, $30 million and $33.3 million at $333 million, $1 billion and $2 billion in cumulative U.S. net sales. - Jupiter will pay a 3% royalty on net sales after the third commercialization milestone. - ALA-002 is a patented, non-racemic MDMA formulation with FDA NCE designation. - The designation provides five-year data exclusivity upon approval. - Jupiter said ALA-002 is designed to improve cardiovascular safety and reduce abuse liability versus racemic MDMA while preserving pro-social and therapeutic effects. - PharmAla’s MDMA supply is already active in U.S. government-sponsored VA and DHA clinical trials. - PharmAla will continue manufacturing ALA-002 drug product for Jupiter under commercial terms to be negotiated. - Jupiter said the arrangement should accelerate development timelines. - Jupiter’s lead program, JOTROL, is in a Phase IIa Parkinson’s disease trial. - Jupiter also commercializes Nugevia, a consumer longevity supplement. - Jupiter’s profile is available in a company profile.

Between the lines: - The deal gives Jupiter a second independent development track, which can reduce reliance on a single asset. - Management is betting that psychedelic medicines will benefit from a more favorable FDA and DEA environment after the April 18, 2026 executive order on serious mental illness treatments. - The company is also signaling a strategy that combines CNS and brain-plasticity assets with regulatory optionality in the U.S. - The forward-looking claims in the release depend on closing conditions, clinical results, regulatory review, financing and other risks.

What's next: - Jupiter and PharmAla still need to complete any remaining closing conditions tied to the agreement. - Jupiter will move toward development and regulatory milestones for ALA-002 while continuing its Parkinson’s program. - PharmAla will continue work on ALA-002 outside the United States. - Jupiter said the next 12 months will be transformative as it executes on both CNS programs.

The bottom line: - Jupiter is using the ALA-002 license to widen its CNS pipeline and add a potentially more valuable U.S. psychedelic asset at a moment of shifting regulatory policy.